These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 32357847

  • 1. Secondary oxalosis induced by xylitol concurrent with lithium-induced nephrogenic diabetes insipidus: a case report.
    Takayasu S, Kamba A, Yoshida K, Terui K, Watanuki Y, Ishigame N, Mizushiri S, Tomita T, Nakamura K, Yasui-Furukori N, Daimon M.
    BMC Nephrol; 2020 May 01; 21(1):157. PubMed ID: 32357847
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial.
    Fotso Soh J, Torres-Platas SG, Beaulieu S, Mantere O, Platt R, Mucsi I, Saury S, Renaud S, Levinson A, Andreazza AC, Mulsant BH, Müller D, Schaffer A, Dols A, Cervantes P, Low NC, Herrmann N, Christensen BM, Trepiccione F, Rajji T, Rej S.
    BMC Psychiatry; 2018 Jul 16; 18(1):227. PubMed ID: 30012135
    [Abstract] [Full Text] [Related]

  • 7. Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus.
    de Groot T, Sinke AP, Kortenoeven ML, Alsady M, Baumgarten R, Devuyst O, Loffing J, Wetzels JF, Deen PM.
    J Am Soc Nephrol; 2016 Jul 16; 27(7):2082-91. PubMed ID: 26574046
    [Abstract] [Full Text] [Related]

  • 8. Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability.
    de Groot T, Doornebal J, Christensen BM, Cockx S, Sinke AP, Baumgarten R, Bedford JJ, Walker RJ, Wetzels JFM, Deen PMT.
    Am J Physiol Renal Physiol; 2017 Sep 01; 313(3):F669-F676. PubMed ID: 28615247
    [Abstract] [Full Text] [Related]

  • 9. [Polyuria and polydipsia due to renal diabetes insipidus during the use of lithium].
    Huyse FJ.
    Ned Tijdschr Geneeskd; 2007 Jan 13; 151(2):152-3. PubMed ID: 17315495
    [No Abstract] [Full Text] [Related]

  • 10. [Polyuria and polydipsia due to renal diabetes insipidus during the use of lithium].
    van Gerven HA, Boer WH.
    Ned Tijdschr Geneeskd; 2006 Aug 05; 150(31):1705-9. PubMed ID: 16924939
    [Abstract] [Full Text] [Related]

  • 11. A case of a novel mutant vasopressin receptor-dependent nephrogenic diabetes insipidus with bilateral non-obstructive hydronephrosis in a middle aged man: differentiation from aquaporin-dependent nephrogenic diabetes insipidus by response of factor VII and von Willebrand factor to 1-diamino-8-arginine vasopressin administration.
    Miyakoshi M, Kamoi K, Uchida S, Sasaki S.
    Endocr J; 2003 Dec 05; 50(6):809-14. PubMed ID: 14709855
    [Abstract] [Full Text] [Related]

  • 12. Central Diabetes Insipidus in the Background of Lithium Use: Consider Central Causes Despite Nephrogenic as the Most Common.
    Li JJ, Tan S, Kawashita T, Tagle CA, Farmand F.
    Am J Case Rep; 2023 Jan 23; 24():e939034. PubMed ID: 36683312
    [Abstract] [Full Text] [Related]

  • 13. The soluble (Pro) renin receptor does not influence lithium-induced diabetes insipidus but does provoke beiging of white adipose tissue in mice.
    Yang KT, Wang F, Lu X, Peng K, Yang T, David Symons J.
    Physiol Rep; 2017 Nov 23; 5(21):. PubMed ID: 29138356
    [Abstract] [Full Text] [Related]

  • 14. Venous thromboembolism and severe hypernatremia in a patient with lithium-induced nephrogenic diabetes insipidus and acute kidney injury: a case report.
    Goo YJ, Song SH, Kwon OI, Kim M, Suh SH, Oh TR, Choi HS, Bae EH, Ma SK, Kim SW, Kim CS.
    Ann Palliat Med; 2022 Aug 23; 11(8):2756-2760. PubMed ID: 34930011
    [Abstract] [Full Text] [Related]

  • 15. Protective effect of metformin on lithium-induced nephrogenic diabetes insipidus: An experimental study in rats.
    Tas HI, Sancak EB.
    Adv Clin Exp Med; 2021 Nov 23; 30(11):1185-1193. PubMed ID: 34595852
    [Abstract] [Full Text] [Related]

  • 16. Genetic deletion of ADP-activated P2Y12 receptor ameliorates lithium-induced nephrogenic diabetes insipidus in mice.
    Zhang Y, Hansson KM, Liu T, Magnell K, Huang Y, Carlson NG, Kishore BK.
    Acta Physiol (Oxf); 2019 Feb 23; 225(2):e13191. PubMed ID: 30257062
    [Abstract] [Full Text] [Related]

  • 17. Persistent nephrogenic diabetes insipidus following lithium therapy.
    Thompson CJ, France AJ, Baylis PH.
    Scott Med J; 1997 Feb 23; 42(1):16-7. PubMed ID: 9226773
    [Abstract] [Full Text] [Related]

  • 18. V2R mutations and nephrogenic diabetes insipidus.
    Bichet DG.
    Prog Mol Biol Transl Sci; 2009 Feb 23; 89():15-29. PubMed ID: 20374732
    [Abstract] [Full Text] [Related]

  • 19. Tamoxifen attenuates development of lithium-induced nephrogenic diabetes insipidus in rats.
    Tingskov SJ, Hu S, Frøkiær J, Kwon TH, Wang W, Nørregaard R.
    Am J Physiol Renal Physiol; 2018 May 01; 314(5):F1020-F1025. PubMed ID: 29357422
    [Abstract] [Full Text] [Related]

  • 20. P2Y12 Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus.
    Zhang Y, Peti-Peterdi J, Müller CE, Carlson NG, Baqi Y, Strasburg DL, Heiney KM, Villanueva K, Kohan DE, Kishore BK.
    J Am Soc Nephrol; 2015 Dec 01; 26(12):2978-87. PubMed ID: 25855780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.